Daniel Afar
94Patents
16h-index
30Co-inventors
84Inventor score
Filing activity: Jun 1, 1999 → Oct 22, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6329503A | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 91 | Expired |
| US7507541B2 | 36P6D5: secreted tumor antigen | Emerging Cross-Sectional Technologies | 77 | Active |
| US9914783B1 | Anti-PD-1 antibodies and their uses | Chemistry; Metallurgy | 50 | Active |
| US7485299B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 44 | Active |
| US7053186B2 | Antibodies immunospecific for STEAP1 | Emerging Cross-Sectional Technologies | 38 | Expired |
| US7037667B1 | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer | Physics | 33 | Expired |
| US8414898B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 33 | Active |
| US6833438B1 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 30 | Expired |
| US6887975B2 | Peptides derived from STEAP1 | Emerging Cross-Sectional Technologies | 30 | Expired |
| US7166714B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 26 | Expired |
| US7641905B2 | Methods of inducing an immune response | Human Necessities | 22 | Expired |
| US7628989B2 | Methods of inducing an immune response | Human Necessities | 22 | Expired |
| US6943235B1 | Transmembrane protein expressed in prostate cancer | Chemistry; Metallurgy | 21 | Expired |
| US7288248B2 | Antibodies against cancer antigen TMEFF2 and uses thereof | Chemistry; Metallurgy | 18 | Expired |
| US7642054B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 16 | Active |
| US7459539B2 | Antibody that binds zinc transporter protein 108P5H8 | Emerging Cross-Sectional Technologies | 16 | Expired |
| US7611904B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 16 | Active |
| US7575749B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 16 | Expired |
| US7319006B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 15 | Expired |
| US7947459B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Physics | 15 | Active |
| US7968307B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 14 | Active |
| US7928201B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 14 | Active |
| US7510840B1 | Method of inhibiting growth or survival of a cell by providing an anti-108P5H8 antibody | Emerging Cross-Sectional Technologies | 14 | Expired |
| US7727533B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 14 | Expired |
| US8603477B2 | Use of anti-CS1 antibodies for treatment of rare lymphomas | Human Necessities | 14 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.